Commentary

Dear Friends and Colleagues,

I am delighted to share with you the excitement of officially launching LymphoSign Journal. The first issue of the Journal will see light according to schedule early in September, thanks to the exceptional dedication of the publishing team at Canadian Science Publishing as well as the sponsorship by Immunodeficiency Canada.

We are all deeply indebted to the extraordinary support we have received from many friends and colleagues who kindly agreed to donate their precious time to serve as editors or members of the Editorial Board, a clear testament to the important role this Journal will play in serving our community of clinicians and scientists who are committed to solving the mysteries of and finding cures for immune disorders.

We are also overwhelmed and encouraged by the number of high quality manuscripts that have already been submitted at this tender age of the Journal. I hope to see this trend continue in the future as we are committed to making LymphoSign Journal a leader in publishing novel observations and research related to the pathogenesis and treatment of inherited immune disorders.

Chaim Roifman

Editor-in-Chief